Figure 3.

The ctDNA gene mutation frequencies changed in patients with PD and in those sensitive to treatment (non-PD). PD was defined in patients who had disease progression within 6 months. Non-PD was defined in patients who were sensitive to treatment and had no disease progression within 6 months. Dark red represents the most common mutated genes and dark blue represents the rarest mutations. If the mutated genes appeared at the same frequency, they are ranked in alphabetic order.

(A) In 16 PD patients, the frequencies of mutations in 102 genes were increased. The most common gene with increased mutations was PIK3CA [asterisk (*) indicates that significantly more PD patients had increased PIK3CA mutation than non-PD patients (56.25% vs 0%, P=.002)].

(B) In 16 PD patients, the frequencies of mutations in 20 genes were decreased. The most common genes with decreased mutations were RET, FAT1, and BRCA1/2.

(C0 In eight therapy-sensitive patients, only nine genes had increased frequencies of mutation. No mutation was more common.

(D) In 8 therapy-sensitive patients, 32 genes had decreased frequencies of mutations. The most common gene with decreased mutations was PIK3CA.